Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MNMD Mind Medicine (MindMed) Inc.

Not Yet Opened 11-25 16:00:00 EST

7.61

+0.05

+0.66%

盘后7.90

+0.29+3.81%

19:56 EST

High8.06	Low7.40	Vol1.32M
Open7.75	D1 Closing7.56	Amplitude8.73%
Mkt Cap558.05M	Tradable Cap513.22M	Total Shares73.33M
T/O10.10M	T/O Rate1.96%	Tradable Shares67.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MNMD","market":"US","secType":"STK","nameCN":"Mind Medicine (MindMed) Inc.","latestPrice":7.61,"timestamp":1732568400000,"preClose":7.56,"halted":0,"volume":1324256,"hourTrading":{"tag":"盘后","latestPrice":7.9,"preClose":7.61,"latestTime":"19:56 EST","volume":107906,"amount":845477.1049,"timestamp":1732582603918},"delay":0,"floatShares":67440700,"shares":73331690,"eps":-1.643455,"marketStatus":"Not Yet Opened","change":0.05,"latestTime":"11-25 16:00:00 EST","open":7.75,"high":8.06,"low":7.4,"amount":10100280.610816,"amplitude":0.087302,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.643455,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732611600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":7.56,"preHourTrading":{"tag":"盘前","latestPrice":7.72,"preClose":7.56,"latestTime":"09:29 EST","volume":9311,"amount":71160.0186183,"timestamp":1732544940078},"postHourTrading":{"tag":"盘后","latestPrice":7.9,"preClose":7.61,"latestTime":"19:56 EST","volume":107906,"amount":845477.1049,"timestamp":1732582603918},"volumeRatio":0.849858,"impliedVol":0.9174,"impliedVolPercentile":0.4365},"requestUrl":"/m/hq/s/MNMD/wiki","defaultTab":"wiki","newsList":[{"id":"2484663143","title":"RBC Capital Remains a Buy on Mind Medicine (MNMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484663143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484663143?lang=en_us&edition=fundamental","pubTime":"2024-11-20 23:15","pubTimestamp":1732115727,"startTime":"0","endTime":"0","summary":"In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Mind Medicine (MNMD – Research Report), with a price target ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-mind-medicine-mnmd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-mind-medicine-mnmd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MNMD","BK4207","BK4547"],"gpt_icon":0},{"id":"2484087726","title":"MindMed Appoints New Chief to Boost Drug Approvals","url":"https://stock-news.laohu8.com/highlight/detail?id=2484087726","media":"TIPRANKS","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484087726?lang=en_us&edition=fundamental","pubTime":"2024-11-19 00:38","pubTimestamp":1731947906,"startTime":"0","endTime":"0","summary":"Mind Medicine (MNMD) has released an update. MindMed has appointed Gregg A. Pratt, Ph.D., as the Chief Regulatory and Quality Assurance Officer to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mindmed-appoints-new-chief-to-boost-drug-approvals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mindmed-appoints-new-chief-to-boost-drug-approvals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","BK4007","MNMD"],"gpt_icon":0},{"id":"2484562920","title":"MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2484562920","media":"Business Wire","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484562920?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931200,"startTime":"0","endTime":"0","summary":"NEW YORK, November 18, 2024----Mind Medicine  Inc. , , a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company’s regulatory and quality functions, as well as its product registration strategies.\"We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen our capabilities and accelerate our progress as we prepare to launch three Phase 3 studies of MM120 orally disintegrating tablet  in generalized anxiety disorder  and major depressive disorder ,\" said Rob Barrow, Chief Executive Officer of MindMed. \"Gregg’s deep expertise in leading the regulatory approvals of transformative psychiatric drugs—demonstrated by his recent leadership in the approval of the first novel schizophrenia treatment in decades—will be key as we ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/A3Mo21waMUHhpCJ9e1pNMA--~B/aD00ODA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/997f2797aa842b96f66bf77a9fa13132","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/A3Mo21waMUHhpCJ9e1pNMA--~B/aD00ODA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/997f2797aa842b96f66bf77a9fa13132"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-appoints-gregg-pratt-ph-120000384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","NQmain","SQQQ",".IXIC","MNMD","BK4547","QID","TQQQ","QLD","MNQmain","ODT","PSQ"],"gpt_icon":1},{"id":"2483872530","title":"Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2483872530","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483872530?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:26","pubTimestamp":1731587210,"startTime":"0","endTime":"0","summary":"Mind Medicine 's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public. 51% of the business is held by the top 15 shareholders. Every investor in Mind Medicine  Inc.  should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 41% to be precise, is retail investors. Put another way, the group faces the maximum upside potential .Retail investors gained the most after market cap touched US$601m last week, while institutions who own 40% also benefitted.In the chart below, we zoom in on the different ownership groups of Mind Medicine .NasdaqGS:MNMD Earnings and Revenue Growth November 14th 2024. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mind-medicine-mindmed-inc-nasdaq-122650773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4547","BK4588","NDAQ","SQQQ","QID","IE00BKPKM429.USD","BK4585","QLD","LU2210149790.SGD","LU2210150020.SGD","BK4112","PSQ","NQmain","TQQQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD",".IXIC","MNMD","MNQmain","BK4007","IE00BGHQF748.EUR"],"gpt_icon":1},{"id":"2483185231","title":"Mind Medicine Set to Engage at Key Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2483185231","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483185231?lang=en_us&edition=fundamental","pubTime":"2024-11-14 04:09","pubTimestamp":1731528589,"startTime":"0","endTime":"0","summary":"Mind Medicine (MNMD) has released an update. Mind Medicine, a biopharmaceutical company focused on brain health disorders, has announced its partic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mind-medicine-set-to-engage-at-key-investor-conferences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mind-medicine-set-to-engage-at-key-investor-conferences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNMD","BK4547","BK4007"],"gpt_icon":0},{"id":"2483984006","title":"MindMed to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2483984006","media":"Business Wire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483984006?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:00","pubTimestamp":1731499200,"startTime":"0","endTime":"0","summary":"NEW YORK, November 13, 2024----Mind Medicine  Inc.  , a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:. Date and Time: Thursday, December 5, 2024 at 11:15 PM ET. Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/o4lcCioA9IKD5ETC6zC.Cw--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/475aa792b60c2597e7242e5c1faf854c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/o4lcCioA9IKD5ETC6zC.Cw--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/475aa792b60c2597e7242e5c1faf854c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-participate-upcoming-investor-conferences-120000102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","NQmain","MNQmain","QLD","BK4547","PSQ","MNMD","TQQQ","QID","BK4007","SQQQ"],"gpt_icon":1},{"id":"2482206243","title":"Mind Medicine Price Target Maintained With a $55.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2482206243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482206243?lang=en_us&edition=fundamental","pubTime":"2024-11-11 18:30","pubTimestamp":1731321000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2024 05:30 ET (10:30 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD"],"gpt_icon":0},{"id":"1189305993","title":"Stock Track | MindMed Shares Soar on Upbeat Earnings and Bullish Analyst Actions","url":"https://stock-news.laohu8.com/highlight/detail?id=1189305993","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189305993?lang=en_us&edition=fundamental","pubTime":"2024-11-10 23:46","pubTimestamp":1731253592,"startTime":"0","endTime":"0","summary":"Shares of Mind Medicine  Inc.  surged by a remarkable 21.01% on Thursday, November 8th, driven by the company's better-than-expected quarterly results and bullish actions from analysts.MindMed, a leading player in the emerging field of psychedelic drug development, reported an adjusted loss of $0.27 per share for the quarter ended September 30. This figure came in narrower than analysts' expectations of a $0.28 per share loss, surprising investors and sparking enthusiasm about the company's perf","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MNMD"],"gpt_icon":0},{"id":"2482066264","title":"Mind Medicine: No News = Good News","url":"https://stock-news.laohu8.com/highlight/detail?id=2482066264","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482066264?lang=en_us&edition=fundamental","pubTime":"2024-11-10 22:55","pubTimestamp":1731250500,"startTime":"0","endTime":"0","summary":"Mind Medicine’s share price has responded very strongly to a third quarter update that contained very little new information.The market appears to have moved to a bullish stance following confirmation","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2152314333/image_2152314333.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2152314333/image_2152314333.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4735863-mind-medicine-no-news-good-news","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4007","BK4547","MNMD"],"gpt_icon":0},{"id":"2481884144","title":"RBC Capital Adjusts Price Target on Mind Medicine to $21 From $20, Maintains Outperform, Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2481884144","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481884144?lang=en_us&edition=fundamental","pubTime":"2024-11-08 23:39","pubTimestamp":1731080357,"startTime":"0","endTime":"0","summary":"Mind Medicine (MindMed) (MNMD) has an average rating of buy and price targets ranging from $14 to $55, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic re","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNMD"],"gpt_icon":0},{"id":"1147863866","title":"Stock Track | Mind Medicine Shares Soar 6% on Upbeat Earnings and Bullish Analyst Actions","url":"https://stock-news.laohu8.com/highlight/detail?id=1147863866","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147863866?lang=en_us&edition=fundamental","pubTime":"2024-11-08 22:37","pubTimestamp":1731076652,"startTime":"0","endTime":"0","summary":"Shares of Mind Medicine  Inc.  surged 6.27% on Thursday, November 8th, driven by the company's better-than-expected quarterly results and positive analyst actions raising price targets and ratings.MindMed reported a quarterly adjusted loss of $0.27 per share for the quarter ended September 30, narrower than the $0.28 per share loss expected by analysts. The company's reported EPS was a loss of $0.27, and it posted a quarterly net loss of $13.68 million, which was an improvement over the same per","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MNMD"],"gpt_icon":0},{"id":"2481517230","title":"Mind Medicine price target raised to $16 from $14 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2481517230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481517230?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:51","pubTimestamp":1731070305,"startTime":"0","endTime":"0","summary":"Canaccord raised the firm’s price target on Mind Medicine (MNMD) to $16 from $14 and keeps a Buy rating on the shares. The firm said they are encou...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mind-medicine-price-target-raised-to-16-from-14-at-canaccord?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mind-medicine-price-target-raised-to-16-from-14-at-canaccord?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MNMD","BK4547"],"gpt_icon":0},{"id":"2481148077","title":"U.S. RESEARCH ROUNDUP-Bath & Body Works, Datadog, Savers value Village","url":"https://stock-news.laohu8.com/highlight/detail?id=2481148077","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481148077?lang=en_us&edition=fundamental","pubTime":"2024-11-08 15:30","pubTimestamp":1731051041,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Bath & Body Works, Datadog, Savers value VillageNov 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL4N3MF0VN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","HAL","BK4110","EMR","HST","ACLX","XRAY","ABNB","EPAM","LYFT","SGXZ51526630.SGD","FLYW","MNMD","IE00B19Z9Z06.USD","NET","ACVA","HAIN","LU0757428866.USD","LU0456854461.SGD","DDOG","FIVN","COTY","PODD","CARS","MNST","BK4198","LU1548497426.USD","FTNT","BSY","CTVA","ANET","ACRE","BRDG","INGN","CPAY","CRC","ASLE","MEG","SG9999011175.SGD","GLUE","FHN","LU0053671581.USD","APD","BILL","MTSI","SVV","IE0008368304.USD","EVH","BBWI","AFRM"],"gpt_icon":1},{"id":"2481903197","title":"Mind Medicine (MindMed) Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481903197","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481903197?lang=en_us&edition=fundamental","pubTime":"2024-11-08 12:47","pubTimestamp":1731041263,"startTime":"0","endTime":"0","summary":"Mind Medicine (MindMed) Inc reports results for the quarter ended in September 30 - Earnings Summary  Mind Medicine (MindMed) Inc MNMD.OQ reported a quarterly adjusted loss of 27 cents per share for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF0C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD"],"gpt_icon":0},{"id":"2481157680","title":"Mind Medicine Q3 2024 GAAP EPS $(0.27) Beats $(0.28) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481157680","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481157680?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:29","pubTimestamp":1731014996,"startTime":"0","endTime":"0","summary":"Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.28) by 3.57 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41825224/mind-medicine-q3-2024-gaap-eps-0-27-beats-0-28-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Mind Medicine Q3 2024 GAAP EPS $(0.27) Beats $(0.28) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD"],"gpt_icon":0},{"id":"2481605135","title":"Massachusetts psychedelics legalization initiative poised to fail","url":"https://stock-news.laohu8.com/highlight/detail?id=2481605135","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481605135?lang=en_us&edition=fundamental","pubTime":"2024-11-06 14:55","pubTimestamp":1730876108,"startTime":"0","endTime":"0","summary":"Yarygin  A Massachusetts ballot question that would allow adults to grow, use, and possess many psychedelic substances appears poised for defeat. With 80% of precincts reporting, opponents of the measure are leading 56.7% to 43.3%. The substances that would be legalized under the proposal are psilocybin and psilocin, which are found in \"magic mushrooms,\" as well as dimethyltryptamine, mescaline, and ibogaine.  Oregon and Colorado already allow the use of some psychedelic substances. Psychedelic drug developers: Mind Medicine , Compass Pathways , Cybin , Atai Life Sciences , Enveric Bio , Revive Therapeutics , Bright Minds Biosciences , GH Research , Clearmind Medicine .","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363506971/image_1363506971.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363506971/image_1363506971.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4253295-massachusetts-psychedelics-legalization-initiative-poised-fail","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["MNQmain","DRUG","BK4139","BK4007","BK4539","CYBN","GHRS","QID","QLD","BK4168","NQmain","MNMD","BK4547","CMPS","ENVB","DRUG.AU",".IXIC","PSQ","CMND","SQQQ","TQQQ","RVVTF","ATAI"],"gpt_icon":1},{"id":"2481552284","title":"Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481552284","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481552284?lang=en_us&edition=fundamental","pubTime":"2024-11-05 05:04","pubTimestamp":1730754259,"startTime":"0","endTime":"0","summary":"Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025.MM-120 is also being tested for MDD in the phase 3 EMERGE st","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2176382509/image_2176382509.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2176382509/image_2176382509.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4732842-mind-medicine-two-pathways-created-from-one-pipeline-clinical-candidate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4547","MNMD","BK4007"],"gpt_icon":0},{"id":"2477859226","title":"Press Release: MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2477859226","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477859226?lang=en_us&edition=fundamental","pubTime":"2024-10-24 19:04","pubTimestamp":1729767840,"startTime":"0","endTime":"0","summary":"MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update. Mind Medicine  Inc.  , a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it plans to host a conference call on Thursday, November 7, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the third quarter ended September 30, 2024.MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD","BK4181","HST","WRD","BK4007","BK4585","BK4588","BK4218","BK4547"],"gpt_icon":0},{"id":"2476058766","title":"FDA is said to see “path forward” for ecstasy-based drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2476058766","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476058766?lang=en_us&edition=fundamental","pubTime":"2024-10-19 21:40","pubTimestamp":1729345202,"startTime":"0","endTime":"0","summary":"Lykos Therapeutics, whose lead asset, midomafetamine capsules (MDMA), failed to win the FDA nod in August, said that the regulator has indicated a path forward for the Ecstasy-based drug, which, if ap","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4178859-fda-is-said-to-see-path-forward-for-ecstasy-based-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["CMPS","BK4007","BK4547","BK4139","MNMD","DRUG","ENVB"],"gpt_icon":1},{"id":"2476923974","title":"Bright Minds rally ends as psychedelic stocks extend volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2476923974","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476923974?lang=en_us&edition=fundamental","pubTime":"2024-10-17 01:55","pubTimestamp":1729101329,"startTime":"0","endTime":"0","summary":"primeimagesAfter a nearly 15-fold rise in value in the previous session, shares of Bright Minds Biosciences (NASDAQ:DRUG) fell ~29% on Wednesday as psychedelic drug developers extended their recent volatility into the afternoon trading. Mind Medicine (MNMD), Cybin (","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1622055565/image_1622055565.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1622055565/image_1622055565.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4166429-bright-minds-stock-cools-amid-psychedelic-volatility","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4007","NQmain","SQQQ",".IXIC","MNMD","DRUG","BK4547","QID","TQQQ","QLD","MNQmain","BK4139","PSQ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mindmed.co","stockEarnings":[{"period":"1week","weight":0.1126},{"period":"1month","weight":0.2579},{"period":"3month","weight":0.2215},{"period":"6month","weight":-0.1459},{"period":"1year","weight":1.5199},{"period":"ytd","weight":1.0792}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.138746},{"month":2,"riseRate":1,"avgChangeRate":0.220255},{"month":3,"riseRate":0.333333,"avgChangeRate":0.135594},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.020489},{"month":5,"riseRate":0.25,"avgChangeRate":-0.037122},{"month":6,"riseRate":0.5,"avgChangeRate":-0.112493},{"month":7,"riseRate":0.75,"avgChangeRate":0.159384},{"month":8,"riseRate":0.25,"avgChangeRate":-0.108659},{"month":9,"riseRate":0,"avgChangeRate":-0.300494},{"month":10,"riseRate":0.5,"avgChangeRate":-0.039054},{"month":11,"riseRate":0.5,"avgChangeRate":0.038255},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.110398}],"exchange":"NASDAQ","name":"Mind Medicine (MindMed) Inc.","nameEN":"Mind Medicine (MindMed) Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mind Medicine (MindMed) Inc.,MNMD,Mind Medicine (MindMed) Inc.股票,Mind Medicine (MindMed) Inc.股票老虎,Mind Medicine (MindMed) Inc.股票老虎国际,Mind Medicine (MindMed) Inc.行情,Mind Medicine (MindMed) Inc.股票行情,Mind Medicine (MindMed) Inc.股价,Mind Medicine (MindMed) Inc.股市,Mind Medicine (MindMed) Inc.股票价格,Mind Medicine (MindMed) Inc.股票交易,Mind Medicine (MindMed) Inc.股票购买,Mind Medicine (MindMed) Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction